Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis

被引：0
|
作者：
Shu, Yongqian
Pan, Yueyin
Lu, Ping
Jiang, Yi
Zhang, Jingdong
Wu, Xiaohong
Yao, Yuanhu
Shen, Lin
Ba, Yi
He, Zhiyong
Bai, Yuxian
Chen, Jianhua
Yu, Guohua
Peng, Yanyan
Wu, Hongqian
Wang, Lei
Li, Liyun
Xu, Jianming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT076
引用
收藏
页数：3
相关论文
共 50 条
  • [21] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Jin Li
    Zhendong Chen
    Yuxian Bai
    Bo Liu
    Qingshan Li
    Jingdong Zhang
    Jun Zhou
    Ting Deng
    Fuyou Zhou
    Shegan Gao
    Shujun Yang
    Feng Ye
    Long Chen
    Wei Bai
    Xianli Yin
    Shundong Cang
    Lianke Liu
    Yueyin Pan
    Hui Luo
    Yanxia Ji
    Zhen Zhang
    Jufeng Wang
    Quanliang Yang
    Na Li
    Rong Huang
    Chenglin Qu
    Jing Ni
    Bo Wang
    Yan Xu
    Jin Hu
    Qingmei Shi
    Jason Yang
    Nature Medicine, 2024, 30 : 740 - 748
  • [22] Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
    Ajani, J.
    El Hajbi, F.
    Cunningham, D.
    Alsina, M.
    Thuss-Patience, P.
    Scagliotti, G. V.
    Van den Eynde, M.
    Kim, S-b.
    Kato, K.
    Shen, L.
    Li, L.
    Ding, N.
    Shi, J.
    Barnes, G.
    Van Cutsem, E.
    ESMO OPEN, 2024, 9 (01)
  • [23] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
  • [24] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [25] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
    Li, Yi
    Zhao, Chuanhua
    Liu, Rongrui
    Xu, Sheng
    Miao, Xiaojie
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413
  • [26] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
    Hiroki Hara
    Taroh Satoh
    Takashi Kojima
    Takahiro Tsushima
    Yu Sunakawa
    Morihito Okada
    Ningning Ding
    Hongqian Wu
    Liyun Li
    Tian Yu
    Gisoo Barnes
    Ken Kato
    Esophagus, 2024, 21 : 102 - 110
  • [27] Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
    Hara, Hiroki
    Satoh, Taroh
    Kojima, Takashi
    Tsushima, Takahiro
    Sunakawa, Yu
    Okada, Morihito
    Ding, Ningning
    Wu, Hongqian
    Li, Liyun
    Yu, Tian
    Barnes, Gisoo
    Kato, Ken
    ESOPHAGUS, 2024, 21 (02) : 102 - 110
  • [28] Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Shi, Fenghao
    He, Zixuan
    Su, Hang
    Wang, Lin
    Han, Sheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] COST EFFECTIVENESS OF TISLELIZUMAB VERSUS CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINA
    Hao, S.
    Han, S.
    VALUE IN HEALTH, 2022, 25 (12) : S136 - S136
  • [30] Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 683 - 690
12345